advanced business communications
advanced business communications with http://www.mdnewscast.net

advanced business communications

Medical Newscast

News for 29-Feb-24

Source: MedicineNet Diabetes General
Chemo More Damaging to Hearts of Diabetics: Study

Source: MedicineNet High Blood Pressure General
Bonus From Your Blood Pressure Med: Fewer Fractures?

Source: MedicineNet High Blood Pressure General
Yoga Called Good Medicine for High Blood Pressure

Source: MedicineNet High Blood Pressure General
Stressed Childhood Might Raise Risk for High Blood Pressure Later

Source: MedicineNet Diabetes General
Health Tip: Prepare for Travel With Diabetes

Source: MedicineNet High Blood Pressure General
Study Finds Worrisome Heart Effects Among Some Football Players

Source: MedicineNet Diabetes General
Can Protein, Probiotics Help With Blood Sugar Control?

Source: MedicineNet Diabetes General
Low Blood Sugar Linked to Death Risk for Hospital Patients

Source: MedicineNet High Blood Pressure General
Even Small Rise in Blood Pressure Can Harm Black Patients

Source: MedicineNet Diabetes General
Jardiance (empagliflozin)

Search the Web
advanced business communications
all business communications
compuserve interactive services
interactive web services
business communications course
moore business communications
emap business communications
interactive tv services
atlantic business communications
business communications services

The Best advanced business communications website

All the advanced business communications information you need to know about is right here. Presented and researched by http://www.mdnewscast.net. We've searched the information super highway far and wide to provide you with the best advanced business communications site on the internet today. The links below will assist you in your efforts to find the information that you are looking for about
advanced business communications.

advanced business communications

Medical Newscast
For information about Medical Newscasts look no further. We have links to great resources regarding all forms of medical internet broadcasting.
Medical Newscast

Many advanced business communications websites invite you to sign a Guestbook. They are not just doing this to get warm fuzzy feelings. advanced business communications retailers who are seriously committed to quality customer service want feedback. The best sort of advanced business communications feedback comes from advanced business communications shoppers. Makes sense doesn't it?

When you take the time to sign a advanced business communications Guestbook you are adding value to the relationship you have with the advanced business communications retailer. You may be able to offer valuable suggestions which will improve the advanced business communications shopping experience for other customers.

advanced business communications

Medical Newscast
For information about Medical Newscasts look no further. We have links to great resources regarding all forms of medical internet broadcasting.
Medical Newscast

If you have struggled to find the wealth of information you need about advanced business communications, then breath a sigh of relief because you have arrived at a web site that contains an abundance of advanced business communications information.

We consider ourselves experts in the field of advanced business communications, we have a great interest in the subject and have dedicated a great amount of our own time sourcing good solid advanced business communications information.

Once we had our database of advanced business communications web sites we sifted through it closely and came to the conclusion most of the entries were just rubbish. However we did find several which we are sure will provide you with exactly the advanced business communications info you are looking for and invite you to click one of the links here.

Class of Drugs Brings Hope to Cancer Patients

 by: ARA Content

(ARA) - This is an exciting time in cancer research. Recent information on angiogenesis -- the growth of new blood vessels -- is providing researchers opportunities to find new ways to slow or stop a tumor's growth by cutting off the blood supply it needs.

Angiogenesis performs a critical role in the development of cancer. To grow, solid tumors need oxygen and nutrients provided by new blood vessels. Once a vascular network has been generated, cancer cells can also invade the rest of the body, a process called metastasis. Currently, researchers believe that more than 90 percent of all cancer cases are angiogenesis-dependent.

The good news is that a novel class of drugs, which acts as angiogenesis inhibitors, shows great potential in fighting more than 20 different diseases, including many types of cancer.

These "anti-angiogenesis" drugs being developed and tested block the formation of new blood vessels, starving cancerous cells and stopping tumor growth. One drug being tested, Neovastat, was discovered in 1994 and is derived from cartilage tissue. Neovastat is the only angiogenesis inhibitor being developed in the biotechnology and pharmaceutical universe that has four mechanisms of action to combat blood vessel growth. Furthermore, Neovastat is taken orally, making it convenient for patients who need long-term treatment, and it has shown minimal side effects in clinical trials. This means that unlike standard chemotherapy, Neovastat is not likely to interfere with a patient's immune system, or cause adverse gastrointestinal symptoms or hair loss.

In addition, because most cancer cells are genetically unstable and more prone to mutations, resistance is a major problem with many chemotherapy agents. But since anti-angiogenesis drugs target normal endothelial cells that are not genetically unstable, drug resistance is less likely to develop and has not been a problem so far in clinical trials.

Another hope is that angiogenesis inhibitors can be used in combination with therapies that directly target tumor cells. Because anti-angiogenic drugs and chemotherapy are aimed at different cellular targets, it is possible that the combination will prove even more effective than either therapy is as a stand-alone.

Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer for which there are urgent needs for new therapies. For multiple myeloma, the second most common form of blood cancer, the drug is in phase two trials with 125 patients in the United States, Canada and Europe. This trial should be completed by the end of 2002. For progressive renal cell carcinoma, the drug is in phase three trials with 280 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a phase three trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005.

Once the clinical trials are complete, health authorities in various countries can then assess test results and make decisions on approval.

Neovastat is being developed by Aeterna Laboratories of Quebec, Canada. For more information about current trials, call (888) 349-3232. If you are an oncologist, contact Claude Hariton, PhD, vice president of Clinical and Regulatory Affairs, (418) 652-8525, Ext. 306.

To learn more about anti-angiogenesis and Aeterna Laboratories, visit the Aeterna Web site at www.aeterna.com. For more information about the NCI's clinical trials, visit http://cancertrials.nci.nih.gov.

About The Author

Courtesy ARA Content, www.ARAcontent.com; e-mail: info@ARAcontent.com

Google

http://www.medmeet.com/
Medical Meetings On The Net | Law Meet | Talk On The Net | Take It Correctly | Medical Newscast

Medical Meetings   Medical Meetings On The Net   MD Newscast